Please use this identifier to cite or link to this item: https://doi.org/10.3390/biom10010023
DC FieldValue
dc.titleAttenuation of STAT3 signaling cascade by daidzin can enhance the apoptotic potential of bortezomib against multiple myeloma
dc.contributor.authorYang, M.H.
dc.contributor.authorJung, S.H.
dc.contributor.authorChinnathambi, A.
dc.contributor.authorAlahmadi, T.A.
dc.contributor.authorAlharbi, S.A.
dc.contributor.authorSethi, G.
dc.contributor.authorAhn, K.S.
dc.date.accessioned2021-08-19T04:56:42Z
dc.date.available2021-08-19T04:56:42Z
dc.date.issued2020
dc.identifier.citationYang, M.H., Jung, S.H., Chinnathambi, A., Alahmadi, T.A., Alharbi, S.A., Sethi, G., Ahn, K.S. (2020). Attenuation of STAT3 signaling cascade by daidzin can enhance the apoptotic potential of bortezomib against multiple myeloma. Biomolecules 10 (1) : 23. ScholarBank@NUS Repository. https://doi.org/10.3390/biom10010023
dc.identifier.issn2218-273X
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/198149
dc.description.abstractDaidzin (DDZ) extracted from Pueraria lobate (Fabaceae) is a widely known phytoestrogen. DDZ can display anti-cancer activities against breast and prostate cancers, but its anti-oncogenic actions in multiple myeloma (MM) cells have not been studied. The signal transducer and activator of transcription 3 (STAT3) can control key processes including proliferation, differentiation, and survival in MM cells. Here, we noted that DDZ abrogated STAT3 activation (both constitutive as well as inducible) at Tyr705 and Ser727 in MM cells. Additionally, DDZ mitigated the phosphorylation of STAT3 upstream Janus-activated kinases (JAK1/2) and c-Src kinases. Pervanadate (tyrosine phosphatase blocker) exposure altered the DDZ-induced inhibition of STAT3 activation, thus affecting the action of this phytoestrogen on apoptosis. Moreover, DDZ impeded proliferation and augmented the apoptotic effects of bortezomib (Bor) in MM cells. Overall, the data indicate that DDZ may act as a potent suppressor of STAT3 signaling cascade, and the co-treatment of DDZ and Bor could be a promising therapeutic strategy, specifically in MM. © 2019 by the authors. Licensee MDPI, Basel, Switzerland.
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScopus OA2020
dc.subjectBortezomib
dc.subjectDaidzin
dc.subjectMultiple myeloma
dc.subjectSTAT3
dc.typeArticle
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.3390/biom10010023
dc.description.sourcetitleBiomolecules
dc.description.volume10
dc.description.issue1
dc.description.page23
dc.published.statePublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3390_biom10010023.pdf2.65 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons